
|Videos|January 2, 2019
Race/Ethnicity and Clinical Outcomes in Breast Cancer
Advertisement
Transcript:
Joseph A. Sparano, MD: There was a very interesting presentation by Dr. Kathy Albain, one of the co-investigators of the TAILORx trial, that focused on the impact of race and ethnicity on clinical outcomes. And there were several really important conclusions that came from this. First of all, about 8% of the patients who enrolled in the trial were African American, and somewhere in the order of 12% or so were of Hispanic ethnicity. When we looked at the clinical characteristics of the black or Hispanic patients versus nonblack or white patients, and Hispanic versus non-Hispanic populations, the clinical characteristics were largely similar
Advertisement
Related to this article

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.

Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.

The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
Five Under 5: Top Oncology Videos for the Week of 9/27
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5






